Preface
MALCOLM WEST,
MALCOLM WEST
Professor, Department of Medicine, University of Queensland, Prince Charles Hospital, Brisbane, Qld
Search for more papers by this author PHIL AYLWARD,
PHIL AYLWARD
Director of Cardiovascular Medicine, Flinders Medical Centre, Adelaide, SA
Search for more papers by this author
MALCOLM WEST,
MALCOLM WEST
Professor, Department of Medicine, University of Queensland, Prince Charles Hospital, Brisbane, Qld
Search for more papers by this author PHIL AYLWARD,
PHIL AYLWARD
Director of Cardiovascular Medicine, Flinders Medical Centre, Adelaide, SA
Search for more papers by this author
First published: 25 March 2008
No abstract is available for this article.
References
- 1
ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1.
Lancet
1988; i: 921–3.
- 2
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.
J Am Coll Cardiol
1988; 12: 3A–13A.
- 3
ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41, 299 cases of suspected acute myocardial infarction.
Lancet
1992; 339: 753–70.
- 4
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction.
Lancet
1995; 345: 669–85.
